DUBLIN--(BUSINESS WIRE)--The "Asthma - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2019, provides an overview of the Asthma (Respiratory) pipeline landscape.
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 15, 47, 32, 2, 111, 27 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Asthma - Overview
- Asthma - Therapeutics Development
- Asthma - Therapeutics Assessment
- Asthma - Companies Involved in Therapeutics Development
- Asthma - Drug Profiles
- Asthma - Dormant Projects
- Asthma - Discontinued Products
- Asthma - Product Development Milestones
- Appendix
Companies Mentioned
- 2A Pharma AB
- 4D Pharma Plc
- AB Science SA
- AbbVie Inc
- Abeome Corp
- Adamis Pharmaceuticals Corp
- Adare Pharmaceuticals Inc
- Advagene Biopharma Co Ltd
- Aerami Therapeutics
- Akeso Biopharma Inc
- Algomedix Inc
- ALK-Abello AS
- Allergan Plc
- Amgen Inc
- Amphastar Pharmaceuticals Inc
- AnaptysBio Inc
- AnGes Inc
- Antisense Therapeutics Ltd
- Apollo Endosurgery Inc
- Apollo Therapeutics LLC
- Aquilon Pharmaceuticals SA
- Argenx SE
- Artax Biopharma Inc
- Artizan Biosciences Inc
- ASIT Biotech SA
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Atrapos Therapeutics LLC
- Aurigene Discovery Technologies Ltd
- Avidin Ltd
- Bai Shuo Beijing Pharmaceutical Technology Co Ltd
- Biocon Ltd
- BiOraliX BV
- BiosanaPharma BV
- Biotec Pharmacon ASA
- Boehringer Ingelheim International GmbH
- Celltrion Inc
- Celon Pharma SA
- Chiesi Farmaceutici SpA
- Chronic Airway Therapeutics Ltd
- ConMed Biosciences Inc
- Crossject SA
- CrystalGenomics Inc
- CSL Ltd
- CSPC Pharmaceutical Group Ltd
- Cumberland Pharmaceuticals Inc
- Cynata Therapeutics Ltd
- Cytokinetics Inc
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Denceptor Therapeutics Ltd
- Dnarx LLC
- EffectorBio Inc
- Eleusis Ltd
- EmphyCorp Inc
- Energenesis Biomedical Co Ltd
- Enterprise Therapeutics Ltd
- Enzychem Lifesciences Corp
- ethris GmbH
- EURRUS Biotech GmbH
- Exotect LLC
- F. Hoffmann-La Roche Ltd
- Fibrotherapeutics Inc
- Foresee Pharmaceuticals Co Ltd
- Fountain Biopharma Inc
- GeneFrontier Corp
- Genentech Inc
- Generium
- GeneScience Pharmaceuticals Co Ltd
- GlaxoSmithKline Plc
- GlycoMira Therapeutics Inc
- Gossamer Bio Inc
- Harbour BioMed
- HEC Pharm Co Ltd
- Hovione FarmaCiencia SA
- Humanigen Inc
- iCeutica Inc
- Icure Pharmaceutical Inc
- IGE Therapeutics Inc
- ILiAD Biotechnologies LLC
- Immune Regulation Ltd
- Inatherys
- InKemia IUCT Group SA
- Innovimmune Biotherapeutics Inc
- Inspyr Therapeutics Inc
- Intech Biopharm Ltd
- Invion Ltd
- Irex Pharma LLC
- JHL Biotech Inc
- JiangSu Qyuns Therapeutics Co Ltd
- Kashiv BioSciences LLC
- KBP BioSciences Co Ltd
- Kissei Pharmaceutical Co Ltd
- Kither Biotech Srl
- KLUS Pharma Inc
- Knopp Biosciences LLC
- KoBioLabs Inc
- Kyowa Kirin Co Ltd
- Laboratorios LETI SL
- Lead Discovery Center GmbH
- LG Chem Ltd
- Lignamed LLC
- Longevity Biotech Inc
- Mabtech Ltd
- Mariposa Health Ltd
- Medicenna Therapeutics Corp
- Mercia Pharma Inc
- Merck & Co Inc
- Mitsubishi Tanabe Pharma Corp
- Mycenax Biotech Inc
- NAL Pharmaceuticals Ltd
- NeoPharm Co Ltd
- Neovacs SA
- Novartis AG
- OliX Pharmaceuticals Inc
- Omeros Corp
- OncoArendi Therapeutics SA
- Oncostellae SL
- Ono Pharmaceutical Co Ltd
- OPKO Health Inc
- Opsidio LLC
- Orbis Biosciences Inc
- Orchid Pharma Ltd
- Oxagen Ltd
- Palo BioFarma SL
- Pantherics Inc
- Paradigm Biopharmaceuticals Ltd
- Paragen Bio Pty Ltd
- Pfizer Inc
- PharmAbcine Inc
- PharmaKing Co Ltd
- Pharmaxis Ltd
- Pieris Pharmaceuticals Inc
- Progenra Inc
- Promedior Inc
- Prommune Inc
- Prous Institute for Biomedical Research SA
- Pulmatrix Inc
- Pulmokine Inc
- Qu Biologics Inc
- Qurient Co Ltd
- RAFT Pharmaceuticals
- RAPT Therapeutics Inc
- Re-Pharm Ltd
- Regeneron Pharmaceuticals Inc
- Reliance Life Sciences Pvt Ltd
- Respiratorius AB
- Revalesio Corp
- ReveraGen BioPharma Inc
- Ribomic Inc
- S-TARget therapeutics GmbH
- Saje Pharma LLC
- Sam-A Pharm Co Ltd
- Seelos Therapeutics, Inc.
- Shanghai Kexin Biotech Co Ltd
- Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co Ltd
- Shouyao Holding Co Ltd
- SolAeroMed Inc
- sterna biologicals Gmbh & Co KG
- Sun Pharma Advanced Research Company Ltd
- Suzhou Connect Biopharmaceuticals Ltd
- Swecure AB
- Synermore Biologics Co Ltd
- Taiho Pharmaceutical Co Ltd
- TaiwanJ Pharmaceuticals Co Ltd
- TCF GmbH
- Tetragenetics Inc
- Teva Pharmaceutical Industries Ltd
- TFF Pharmaceuticals Inc
- The Geneva Biotech Center SA
- Theravance Biopharma Inc
- Torrent Pharmaceuticals Ltd
- Translational Biosciences
- Trio Medicines Ltd
- Tunitas Therapeutics Inc
- United BioPharma Inc
- Vactech Oy
- Vascular BioSciences
- Vasomune Inc
- Vectura Group Plc
- Verona Pharma Plc
- WhanIn Pharmaceutical Co Ltd
- Xencor Inc
- Yuhan Corp
- Zai Lab Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sos1y3
